[Letter to the Editor] Genetic Control
By Marcy Darnovsky,
The New Yorker
| 12. 14. 2015
Specter highlights exciting developments in the field of gene editing, but he is too quick to dismiss the shadow side. Writing that CRISPR “offers a new outlet for the inchoate fear of tinkering with the fundamentals of life” is an inadequate characterization of the risks involved. The piece describes a nightmare of Jennifer Doudna’s, in which she tutors Hitler about editing genes, but does not reference Eric Lander’s sober warning, in an article on heritable genome manipulation, in the New England Journal of Medicine. Specter does not mention that dozens of countries, including most with developed biotech sectors, have written prohibitions on heritable genetic manipulation into their laws, and into a binding international treaty. In distinguishing the public—and its advocates—from scientists, Specter might lead readers to erroneously believe that researchers are not deeply concerned. Nearly all scientists want a broad public debate about what kind of gene editing should be pursued. This is a potentially society-altering technology, and democratic engagement with its trajectory is crucial and pressing.
Marcy Darnovsky
Executive Director, Center for Genetics and Society
Berkeley, Calif.
Related Articles
What We Inherit by Sam Trejo and Daphne O. Martschenko; and Original Sin by Kathryn Paige Harden have a great deal in common, with substantial differences in style and emphasis. Both books attempt, in different ways, to show the reader just where current research into human genomics stands, where that might be going, and why the authors are interested. In short, the influence of genomic research on our societies is already large and seems likely to change them in ways...
By Dan Falk, Nautilus | 08.20.2026
The pseudoscience of eugenics, founded on the mistaken notion that nature envisions some “right” combination of genes, and that selective breeding can improve the human race, is making a comeback. While the heyday of eugenics was a century ago, the...
By Emily Packard Dawson and Lainie Friedman Ross, MedPage Today | 08.18.2026
Few things evoke a greater sense of desperation than a parent seeking an experimental treatment for their child. That desperation can make even extraordinary risks seem worth taking. This dynamic has come into stark relief after Mei, a 6-year-old girl...
By Ryan Cross, Endpoints News | 08.20.2026
China’s cheap, fast and quiet system for testing cutting-edge medicines is facing scrutiny after the deaths of three people in investigator-initiated trials.
The studies, also known as IITs, allow experimental cell and gene therapies to be tested without oversight from...